Diamonds and Dogs
NephroGenex Inc. (NRX)
NephroGenex is skyrocketing today, up 204.09% to $14.14. The pharmaceutical company that focuses on kidney treatment saw its shares pop after it announced that its lead drug was found to be safe in a cardiac safety study. NephroGenex is evaluating the drug pyridorin in a late-stage trial in patients with diabetic nephropathy, a chronic and degenerative kidney disease caused by diabetes and often tied to heart disease. The company had previously noted possible concerns regarding cardiac safety with the drug, but those concerns are now put to rest. Shares of NephroGenex climbed nearly $9.50 today, and were up much higher early in the day when they reached a new 52-week high of $17.98.
Hercules Offshore Inc. (HERO)
Hercules has lost its strength today, down 2.94% to $0.99, capping off a horrendous 2014. The shallow off-shore drilling company is finishing a bad year on a down note, after starting the year at $6.74. Hercules has been hit by numerous sell-offs and downgrades; most recently. Global Hunter Securities lowered their price target from $0.90 to $.80. Shares of Hercules aren't any investor's hero this year and Jefferies analysts believe that even with the recent hit in offshore drillers, now is not the time to long. Shares of Hercules hit a new 52-week low of $0.97.
Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.